wrwycr-NH2 TFA (GMP Grade Peptide)

描述

wrwycr-NH2 TFA is a synthetic peptide designed for advanced cancer research studies. This peptide has gained attention due to its ability to selectively target tumor cells by inducing DNA damage and cell cycle arrest, leading to reduced proliferation of cancer cells. Unlike many cytotoxic agents, wrwycr-NH2 TFA does not trigger endoplasmic reticulum (ER) stress, suggesting a unique mechanism of action that minimizes interference with protein-folding pathways.

Studies indicate that wrwycr-NH2 TFA displays significant anti-tumor activity, particularly when administered alongside DNA-damaging agents such as chemotherapy drugs. The synergistic effect enhances its therapeutic potential in experimental oncology models, making it a valuable tool for researchers investigating combination cancer therapies.

As a GMP-certified peptide, wrwycr-NH2 TFA is produced under strict manufacturing standards to ensure high purity, consistency, and reproducibility, making it suitable for both small-scale academic research and large-scale institutional projects.

This peptide is provided with a high degree of purity and stability, supporting reliable results in experimental setups. Its distinct profile makes wrwycr-NH2 TFA particularly useful in exploring novel therapeutic strategies, biomolecular pathways of DNA repair, and mechanisms of tumor cell resistance.

Note: wrwycr-NH2 TFA is supplied exclusively for laboratory research purposes. It is not intended for human use, clinical treatment, or diagnostic applications.

Product Specifications

Mechanism of Action & Research Applications

wrwycr-NH2 TFA operates through a distinct DNA-targeting mechanism that makes it especially relevant in cancer research. The peptide binds to and disrupts DNA replication and repair processes, resulting in DNA damage accumulation within tumor cells. As the damaged DNA remains unrepaired, wrwycr-NH2 TFA enforces cell cycle arrest, halting further proliferation of malignant cells.

Importantly, wrwycr-NH2 TFA is unique in that it does not trigger ER stress, distinguishing it from conventional cytotoxic compounds. This specificity provides researchers with a clean model for studying DNA-damage-induced apoptosis without confounding factors related to protein misfolding or ER-related pathways.

In cancer research, wrwycr-NH2 TFA has shown:

• Cytotoxicity across multiple tumor cell lines, indicating broad anti-cancer potential.

• Potent synergy with DNA-damaging agents, suggesting its use as a combination therapy enhancer.

• Applications in DNA repair pathway studies, particularly in examining tumor cell resistance.

• Exploratory use in drug discovery, as a model compound for understanding peptide-based anti-tumor strategies.

Research applications extend to:

• Investigating novel peptide-based cancer therapeutics.

• Developing synergistic treatment regimens with established chemotherapeutics.

• Studying DNA damage signaling pathways and cancer cell checkpoint regulation.

• Exploring mechanisms of tumor cell apoptosis and resistance suppression.

  

Side Effects (For Research Reference Only)

In laboratory models, wrwycr-NH2 TFA has demonstrated cytotoxicity against tumor cells while sparing endoplasmic reticulum stress pathways. Observed side effects in research settings may include:

• Induction of DNA double-strand breaks leading to cell cycle arrest.

• Activation of apoptosis pathways in susceptible tumor cell lines.

• Potential off-target cytotoxic effects in non-malignant cells under high concentrations.

• Synergistic toxicity when combined with other DNA-damaging agents, requiring careful dosage adjustments in experimental models.

These effects are relevant only in laboratory experiments and should be interpreted in the context of research environments.

Disclaimer: wrwycr-NH2 TFA is for laboratory research use only. Not for human consumption, medical, or diagnostic use.

Disclaimer

wrwycr-NH2 TFA is manufactured in a GMP-certified facility to ensure the highest quality standards for laboratory research. This product is intended solely for research applications. It is not approved for use in humans, animals, clinical trials, or diagnostic purposes. Researchers should handle the peptide with appropriate safety protocols.